Publications by authors named "Steffen Bayerschmidt"
Background: The purpose of this study was to evaluate the safety and outcome of rechallenge [Lu]Lu-PSMA-I&T in newly progressed mCRPC patients after response to initial [Lu]Lu-PSMA radioligand therapy (PRLT).
Methods: We retrospectively included 18 patients who underwent rechallenge with [Lu]Lu-PSMA-I&T. All patients presented with (i) newly progressed disease after response to initial PRLT; (ii) a [Ga]Ga-PSMA-11 PET/CT confirming the presence of PSMA-positive metastases; iii) ECOG performance status 0-1.
PET/CT with the new Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(-Me)Nle-Asp-1-Nal-NH (Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokinin-2 receptor expression status. Six patients with advanced MTC underwent PET/CT with Ga-DOTA-MGS5. From the images acquired 1 and 2 h after injection, preliminary data on the biodistribution and tumor-targeting properties were evaluated in a retrospective analysis.
View Article and Find Full Text PDFNephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
May 2022
Purpose: Nephro- and hematotoxicity after peptide receptor radionuclide therapy (PRRT) have been described in multiple studies with heterogeneous cumulative activities, number of cycles or radiolabelled peptides. Though highly differentiated metastasized neuroendocrine tumours (NET) have long progression free survival, they may progress. We analysed long-term side effects in a homogenous treatment schedule in PRRT-patients and their impact on future oncologic treatment in case of progression.
View Article and Find Full Text PDFBackground: 68Ga-PSMA-11 PET/CT is a promising method for the assessment of local recurrence (LR) in prostate cancer (PCa) patients. The aim of this study was to evaluate the diagnostic performance of early 68Ga-PSMA-11 PET imaging in comparison to 68Ga-PSMA-11 PET imaging 60 min post-injection (p.i.
View Article and Find Full Text PDFThe aim of this study was twofold. First, we aimed to assess the impact of forced diuresis with early furosemide injection on the detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (Ga-PSMA-11) PET/CT. Second, we determined whether intravenous administration of furosemide shortly after tracer injection increases renal washout of Ga-PSMA-11 before it binds to the PSMA receptor with possible influence on biodistribution and intensity of tracer uptake in organs with physiologic tracer accumulation.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how intravenous hydration and two dosages of furosemide (20 vs 40 mg) affect tracer accumulation and halo artifacts in [Ga]Ga-PSMA-11-PET/CT scans for patients with prostate cancer.
- It involves four groups of 50 patients each, varying in preparation methods, including no preparation, sodium chloride alone, and sodium chloride combined with either dosage of furosemide.
- Results show a significant reduction in halo artifacts around the bladder with 20 mg furosemide compared to no preparation or sodium chloride alone, while no significant differences were found in renal halo artifacts among the groups.